Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
A Personal View published in The Lancet Oncology challenges the long-standing perception of metastatic brain cancer, calling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results